Cargando…

Editorial: Incretin agonists in the treatment of obesity

Detalles Bibliográficos
Autores principales:	Sun, Xiaodong, Hu, Miaofen G., Li, Lixin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10446470/ https://www.ncbi.nlm.nih.gov/pubmed/37621651 http://dx.doi.org/10.3389/fendo.2023.1265826

Ejemplares similares

Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
por: Tan, Qiming, et al.
Publicado: (2022)

Exposure–Response Analysis of Cardiovascular Outcome Trials With Incretin-Based Therapies
por: Pan, Qi, et al.
Publicado: (2022)

Treatment with the dual-incretin agonist DA-CH5 demonstrates potent therapeutic effect in a rat model of Wolfram Syndrome
por: Jagomäe, Toomas, et al.
Publicado: (2023)

Incretin hormones as immunomodulators of atherosclerosis
por: Alonso, Nuria, et al.
Publicado: (2012)

The Origin and Understanding of the Incretin Concept
por: Rehfeld, Jens F.
Publicado: (2018)

NDRG1 Activity in Fat Depots Is Associated With Type 2 Diabetes and Impaired Incretin Profile in Patients With Morbid Obesity
por: Stafeev, Iurii, et al.
Publicado: (2021)

From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
por: Holst, Jens Juul
Publicado: (2019)

Beyond Glycemic Control in Diabetes Mellitus: Effects of Incretin-Based Therapies on Bone Metabolism
por: Ceccarelli, Elena, et al.
Publicado: (2013)

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
por: Wang, Jing-Yue, et al.
Publicado: (2023)

Gene x Gene Interactions Highlight the Role of Incretin Resistance for Insulin Secretion
por: Jaghutriz, Benjamin Assad, et al.
Publicado: (2019)

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
por: Holst, Jens Juul, et al.
Publicado: (2020)

Impact of Incretin Hormone Receptors on Insulin-Independent Glucose Disposal in Model Experiments in Mice
por: Ovlund, Tina, et al.
Publicado: (2021)

Niacin exacerbates β cell lipotoxicity in diet-induced obesity mice through upregulation of GPR109A and PPARγ2: Inhibition by incretin drugs
por: Zhang, Xiaojing, et al.
Publicado: (2022)

Effects of Incretin Pathway Elements on Bone Properties
por: Abdi, Arezoo M, et al.
Publicado: (2023)

Editorial: Peripheral Regulators of Obesity
por: McAinch, Andrew J., et al.
Publicado: (2019)

Editorial: “Linking Hypoxia to Obesity”
por: Foti, Daniela P., et al.
Publicado: (2017)

Editorial: Covid-19 and obesity
por: Guglielmi, Valeria, et al.
Publicado: (2022)

Editorial: (Osteo)Sarcopenia & sarcopenic obesity
por: Masiero, Stefano, et al.
Publicado: (2023)

Editorial: Hypothalamic obesity: Today and future
por: van Santen, H.M., et al.
Publicado: (2022)

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
por: Gallwitz, Baptist
Publicado: (2022)

Detour Ahead: Incretin Hormone Signaling Alters Its Intracellular Path as β-Cell Failure Progresses During Diabetes
por: Hussain, Mehboob A., et al.
Publicado: (2021)

A review on phytochemical and pharmacological facets of tropical ethnomedicinal plants as reformed DPP-IV inhibitors to regulate incretin activity
por: Chhabria, Srishti, et al.
Publicado: (2022)

Editorial: A year in review: discussions in obesity
por: Yadegar, Abbas, et al.
Publicado: (2023)

Editorial: Obesity, Smoking, and Fatty Liver Disease
por: Sinha-Hikim, Amiya P., et al.
Publicado: (2018)

Editorial: Diabetes and Obesity Effects on Lung Function
por: Chen, Xiao-Feng, et al.
Publicado: (2020)

Editorial: Cardiovascular Diseases Related to Diabetes and Obesity
por: Rajesh, Mohanraj, et al.
Publicado: (2022)

Editorial: Endocrine and metabolic consequences of childhood obesity
por: Molnár, Dénes, et al.
Publicado: (2022)

Editorial: Leptin, obesity and diet at a glance
por: Hryciw, Deanne H., et al.
Publicado: (2022)

Editorial: The relationship between sarcopenia and metabolic diseases: Its formation mechanism and intervention means
por: Cheng, Qingfeng, et al.
Publicado: (2022)

Editorial: Research Topic for Frontiers in Endocrinology (Obesity): Fetal Origin of Obesity and Diabetes
por: Sliwowska, Joanna H., et al.
Publicado: (2022)

Editorial: GnRH agonist triggering of final oocyte maturation: Improving safety without compromising success
por: Awwad, Johnny, et al.
Publicado: (2023)

A Combination of Glucagon-Like Peptide-1 Receptor Agonist and Dietary Intervention Could Be a Promising Approach for Obesity Treatment
por: Lee, Chooi Yeng
Publicado: (2021)

Editorial: Clinical and genetic determinants of diabetes and complications
por: Li, Sen, et al.
Publicado: (2023)

Editorial: (Osteo)sarcopenia & sarcopenic obesity, volume II
por: Kostoglou-Athanassiou, Ifigenia, et al.
Publicado: (2023)

Editorial: Dietary Factors, Epigenetics and Their Implications for Human Obesity
por: Vohl, Marie-Claude, et al.
Publicado: (2020)

Editorial: Metabolically Healthy and Unhealthy Obese Children and Adolescents
por: Chiesa, Claudio, et al.
Publicado: (2020)

Editorial: The Role of Obesity and Metabolic Syndrome in Couple Infertility
por: Marchiani, Sara, et al.
Publicado: (2021)

Editorial: Connecting the Dots Between Obesity, Diabetes and Cancer
por: Tong, Xuemei, et al.
Publicado: (2020)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Editorial: The Impact of Adipose Tissue Dysfunction on Cardiovascular and Renal Disease
por: Sun, Xiaodong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g1u3qcif7sr0f3rcrokk4ed931